Results 131 to 140 of about 354,322 (345)

Identification Epitope on VP4 Protein of Senecavirus A Recognized by a Monoclonal Antibody

open access: yesAnimal Research and One Health, EarlyView.
This study aims to identify conserved antigenic epitopes on the SVA VP4 protein using monoclonal antibodies, providing valuable tools for further exploring its functions and developing detection methods. SVA VP4 protein was expressed in Escherichia coli and purified with High‐Affinity Ni‐Charged Resin FF.
Liang Meng   +7 more
wiley   +1 more source

A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity [PDF]

open access: gold, 2015
Tracy E. Garrett   +10 more
openalex   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population

open access: yesClinical Anatomy, EarlyView.
ABSTRACT This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as ...
Amy C. Beresheim, Amanda Hall
wiley   +1 more source

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications

open access: yesBlood Cancer Journal, 2021
Hiroto Ohguchi   +2 more
doaj   +1 more source

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clinical trials are essential to understand the benefit‐harm profile of new drugs. Lack of adequate representation in age and sex ratio in clinical trials can result, for example, in higher side effects for underrepresented patients. We quantified differences in age and sex ratios between trial and target populations of new drugs approved by the FDA ...
Miquel Serra‐Burriel   +2 more
wiley   +1 more source

Role of minimal residual disease assessment in multiple myeloma

open access: yesHaematologica
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy